Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 23, 2025, titled "Zydus receives final approval from USFDA for Isotretinoin Capsules USP, 10 mg 20 mg, 25 mg, 30 mg, 35 mg and 40 mg".
Press Release May 23 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it has received final approval from the USFDA for Isotretinoin Capsules in various strengths. These capsules are intended for the treatment of severe, disfiguring nodular acne and will be manufactured at the company's facility in Moraiya, Ahmedabad. The press release highlights that Isotretinoin capsules had significant annual sales in the United States, indicating a strong market presence.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 20 2025
- Press Release May 14 2025
- Press Release May 08 2025
- Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
- Press Release Apr 30 2025
Later from Zydus Lifesciences
- Press Release May 28 2025
- Zydus Lifesciences Limited Press Release Jun 02 2025
- Press Release Jun 10 2025
- Press Release Jun 11 2025
- Press Release Jun 18 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences